Washington Capital Management Inc. held its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,400 shares of the biopharmaceutical company’s stock at the end of the second quarter. Washington Capital Management Inc.’s holdings in Intercept Pharmaceuticals were worth $291,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the stock. Norges Bank acquired a new position in Intercept Pharmaceuticals during the fourth quarter valued at $17,652,000. MARSHALL WACE ASIA Ltd acquired a new position in Intercept Pharmaceuticals during the first quarter valued at $13,012,000. Marshall Wace North America L.P. acquired a new position in Intercept Pharmaceuticals during the first quarter valued at $13,012,000. Macquarie Group Ltd. boosted its position in Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after buying an additional 84,954 shares during the period. Finally, Vanguard Group Inc. boosted its position in Intercept Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock valued at $143,749,000 after buying an additional 56,952 shares during the period. 83.93% of the stock is currently owned by institutional investors.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) traded up 2.05% during mid-day trading on Friday, hitting $103.19. The stock had a trading volume of 343,264 shares. The stock has a 50 day moving average price of $120.81 and a 200 day moving average price of $117.78. Intercept Pharmaceuticals, Inc. has a 52 week low of $96.63 and a 52 week high of $172.95. The firm’s market cap is $2.59 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. During the same quarter in the previous year, the firm earned ($3.14) EPS. Intercept Pharmaceuticals’s revenue was up 459.6% on a year-over-year basis. Equities research analysts expect that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current fiscal year.
Several equities research analysts recently commented on the company. Cantor Fitzgerald reissued an “underweight” rating and issued a $69.00 price target (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday. BidaskClub cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Laidlaw reaffirmed a “hold” rating and set a $119.00 target price (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Finally, BMO Capital Markets upped their target price on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $203.67.
In other news, CMO David Shapiro sold 1,118 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $119.00, for a total transaction of $133,042.00. Following the completion of the transaction, the chief marketing officer now owns 45,680 shares of the company’s stock, valued at approximately $5,435,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel G. Welch sold 602 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $123.93, for a total value of $74,605.86. Following the transaction, the director now directly owns 3,108 shares of the company’s stock, valued at approximately $385,174.44. The disclosure for this sale can be found here. Insiders have sold a total of 47,575 shares of company stock valued at $6,144,469 in the last three months. 9.20% of the stock is owned by insiders.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.